Integrase Inhibitors: all 515 studies that test it

Page 1 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingNCT07792096Phase 3
• Optimization of Antiretroviral Therapy in Patients With AIDS-Related LymphomaRecruitingNCT07727642Not applicable
• Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingNCT07708727Phase 2/3
• Cabotegravir-Hormone PK/PD Interactions for HIV PreventionRecruitingNCT07672717Phase 1
• A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingNCT07645287Phase 2
• Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenRecruitingNCT07616739Phase 4
• REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingNCT07476339Phase 4
• A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingNCT07275606Phase 1/2
• Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsRecruitingNCT07199335Phase 4
• Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpRecruitingNCT07138144Phase 4
• Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingNCT07031063Phase 4
• Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)RecruitingNCT06967753Phase 4
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoRecruitingNCT06907056Phase 4
• NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral SettingsNot yet recruitingNCT06854029Phase 4
• Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsRecruitingNCT06805656Phase 2
• Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.Not yet recruitingNCT06787976Phase 4
• Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)Not yet recruitingNCT06580873Phase 4
• Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentRecruitingNCT06497465Phase 3
• The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingNCT06375304Phase 4
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingNCT06337032Phase 4
• Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionRecruitingNCT06281834Phase 1
• Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.Not yet recruitingNCT06273943Phase 3
• Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingNCT06250504Phase 3
• Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingNCT06133686Phase 3
• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingNCT05674656Phase 1/2
• Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingNCT05652478Phase 2
• Pharmacokinetics and Safety of DolutegravIr in NeonateRecruitingNCT05590325Phase 1/2
• The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirRecruitingNCT05515770Phase 3
• Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF ToxicityNot yet recruitingNCT05493969Phase 4
• Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight GainRecruitingNCT05463783Phase 4
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingNCT05418868Phase 1
• Kuwa Free! - Live Free!RecruitingNCT05044962Not applicable
• Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TBRecruitingNCT04746547Phase 4
• The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.RecruitingNCT04258475Phase 4
• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingNCT02140255Phase 1/2
• Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)CompletedNCT06104306Phase 4Results posted
• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFCompletedNCT05911360Phase 3Results posted
• A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsCompletedNCT05896761Phase 3Results posted
• Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyCompletedNCT05896748Phase 3Results posted
• Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding VolunteersCompletedNCT05648201Phase 4Results posted
• Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated TuberculosisCompletedNCT05630872Phase 2Results posted
• Study of Novel Antiretrovirals in Participants With HIV-1CompletedNCT05585307Phase 1Results posted
• SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionCompletedNCT05549726Phase 4Results posted
• A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedNCT05514509Phase 4Results posted
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Active, not recruitingNCT05502341Phase 2/3Results posted
• A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1CompletedNCT05406583Phase 1Results posted
• Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)CompletedNCT05405751Phase 4Results posted
• A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesCompletedNCT05374525Phase 4Results posted
• Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingNCT05052996Phase 2Results posted
• Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)CompletedNCT04982445Phase 4Results posted
• Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to LamivudineCompletedNCT04880785Phase 2Results posted
• Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3CompletedNCT04880395Phase 4Results posted
• Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis RegimensCompletedNCT04860505Phase 4Results posted
• A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy ParticipantsCompletedNCT04857892Phase 1Results posted
• A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult ParticipantsCompletedNCT04827134Phase 1Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent FemalesCompletedNCT04824131Phase 2Results posted
• The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy VolunteersCompletedNCT04771754Phase 1Results posted
• INSTI's For The Management of HIV-associated TBCompletedNCT04734652Phase 2Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedNCT04692077Phase 2Results posted
• Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services ProgramCompletedNCT04650269Phase 4Results posted
• Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAFCompletedNCT04585737Phase 4Results posted
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedNCT04542070Phase 3Results posted
• Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal TransplantCompletedNCT04530630Phase 4Results posted
• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedNCT04484337Phase 1Results posted
• Pharmacokinetics of JULUCA in HemodialysisCompletedNCT04431518Phase 4Results posted
• A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesCompletedNCT04399551Phase 3Results posted
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedNCT04371380Phase 1Results posted
• Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected IndividualsTerminatedNCT04272242Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVCompletedNCT04143594Phase 2Results posted
• Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSMCompletedNCT04039217Phase 4Results posted
• Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)CompletedNCT04021290Phase 3Results posted
• Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usECompletedNCT03998176Phase 4Results posted
• Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled TrialCompletedNCT03991013Phase 2Results posted
• Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese DescentCompletedNCT03984838Phase 1Results posted
• Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersCompletedNCT03960645Phase 1Results posted
• Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03945981Phase 3Results posted
• Dolutegravir Pediatric Liquid Formulation StudyCompletedNCT03921723Phase 1Results posted
• Standard Versus Double Dose Dolutegravir in Patients With HIV-associated TuberculosisCompletedNCT03851588Phase 2Results posted
• Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)CompletedNCT03816696Phase 1Results posted
• B/F/TAF Switch Study for HIV-HBV CoinfectionCompletedNCT03797014Phase 4Results posted
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1CompletedNCT03739996Phase 2Results posted
• The Late Presenter Treatment Optimisation StudyCompletedNCT03696160Phase 3Results posted
• Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected AdolescentsCompletedNCT03682848Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)CompletedNCT03667547Phase 4Results posted
• Effects of Biktarvy on CFR in Stable HIV PatientsCompletedNCT03656783Phase 3Results posted
• Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE StudyCompletedNCT03639311Phase 2Results posted
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedNCT03635788Phase 3Results posted
• Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsCompletedNCT03547908Phase 3Results posted
• A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsCompletedNCT03537404Phase 1Results posted
• B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected AdultsTerminatedNCT03532425Phase 4Results posted
• Rapid HIV Treatment Initiation, Access and Engagement in CareCompletedNCT03512964Not applicableResults posted
• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsCompletedNCT03497676Phase 1/2Results posted
• Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)CompletedNCT03446573Phase 3Results posted
• Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsCompletedNCT03405935Phase 3Results posted
• Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to RaltegravirCompletedNCT03374358Phase 4Results posted
• Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant PatientsCompletedNCT03360682Phase 4Results posted
• Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMCompletedNCT03311945Phase 3Results posted
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3Results posted
• ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-AdherenceCompletedNCT03218592Phase 4Results posted

← Integrase Inhibitors overview